Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Natural Alternatives International, Inc. (NAII) is a U.S.-based nutritional supplement and nutraceutical company operating within the dietary supplements, sports nutrition, and health and wellness industries. The company develops, manufactures, and commercializes proprietary and private‑label nutritional products, with a core focus on amino acids and performance‑enhancing ingredients. NAII’s business is driven by both branded ingredient sales and contract manufacturing services for third‑party brands, serving customers ranging from global consumer packaged goods companies to specialty sports nutrition firms.
A defining aspect of NAII’s positioning is its ownership of patented and trademarked ingredients, most notably CarnoSyn® beta‑alanine, which is widely used in sports performance and endurance products. The company leverages scientific research, intellectual property protection, and regulatory compliance as strategic advantages. Founded in 1980, NAII initially operated as a contract manufacturer and gradually evolved into an intellectual‑property‑focused nutraceutical company following the development and commercialization of CarnoSyn® in the early 2000s.
Business Operations
NAII operates primarily through two core business segments: Branded Ingredients and Contract Manufacturing. The branded ingredients segment centers on the development, licensing, and sale of patented compounds, including sustained‑release and specialty formulations marketed under the CarnoSyn® family. Revenue in this segment is generated through ingredient sales and licensing arrangements with supplement brands and manufacturers.
The contract manufacturing segment provides formulation, encapsulation, tableting, packaging, and quality assurance services for dietary supplement companies. Operations are conducted through wholly owned subsidiaries, including CarnoSyn Brands, LLC and Natural Alternatives Manufacturing, Inc. Manufacturing, quality control, and R&D activities are primarily U.S.-based. Data inconclusive based on available public sources regarding any material joint ventures outside these wholly owned subsidiaries.
Strategic Position & Investments
NAII’s strategy emphasizes protection and monetization of intellectual property, expansion of patented ingredient applications, and long‑term supply relationships with established supplement brands. The company has historically invested in clinical research to support ingredient efficacy and to strengthen regulatory and marketing claims, particularly around human performance, endurance, and healthy aging.
Rather than pursuing frequent large acquisitions, NAII’s investments have focused on patent portfolios, trademarks, and process technologies related to amino acid synthesis and delivery systems. CarnoSyn® and SR CarnoSyn® remain central to the company’s growth strategy, with ongoing efforts to extend their use into new product categories and international markets. Data inconclusive based on available public sources regarding material equity investments in unrelated portfolio companies.
Geographic Footprint
NAII is headquartered in Carlsbad, California, and its primary manufacturing and research operations are located in the United States. The company’s operational footprint is domestic, but its commercial reach is international through sales of branded ingredients and manufactured products to customers across North America, Europe, and parts of the Asia‑Pacific region.
International exposure is primarily customer‑driven rather than asset‑based, with NAII supplying ingredients and finished products that are distributed globally by its clients. The company’s intellectual property protections extend into multiple jurisdictions, supporting international licensing and enforcement activities.
Leadership & Governance
NAII is led by a management team with long tenure in nutraceutical manufacturing, intellectual property management, and regulatory compliance. Leadership emphasizes scientific validation, quality manufacturing standards, and disciplined capital allocation as core elements of corporate strategy.
Key executives include:
- Mark A. LeDoux – Chairman of the Board and Chief Executive Officer
- Douglas W. Brown – Chief Financial Officer
- Data inconclusive based on available public sources regarding additional executive officers with consistently disclosed operational titles across recent filings